D68.318 - Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors
- Applicable to Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors
- The 2025 edition of ICD10-CM D68.318 became effective on October 1, 2024.
- This is the American ICD10-CM version of D68.318 - other international versions of ICD10 D68.318 may differ.
- D68.318 is a Billable / Specific ICD10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
Inclusion terms help to clarify and specify the conditions or diseases covered by a particular ICD-10-CM code.
Inclusion Term:
- Antithromboplastinemia
- Antithromboplastinogenemia
- Hemorrhagic disorder due to intrinsic increase in antithrombin
- Hemorrhagic disorder due to intrinsic increase in anti-VIIIa
- Hemorrhagic disorder due to intrinsic increase in anti-IXa
- Hemorrhagic disorder due to intrinsic increase in anti-XIa
Billable/Specific Code
The following codes above D68.318 contain annotation back-references that may be applicable to D68.318:
- Chapter: D50-D89 - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Section: D65-D69 - Coagulation defects, purpura and other hemorrhagic conditions
- Category: D68 - Other coagulation defects
Browse other similar CM codes:
Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.
Please, give attribution to our website icd10all.com